Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yeh Chen Lee, Michael Michael & John R Zalcberg. (2015) An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer. Expert Opinion on Investigational Drugs 24:10, pages 1307-1320.
Read now
Read now
Toni M. Brand, Emily F. Dunn, Mari Iida, Rebecca A. Myers, Kellie T. Kostopoulos, Chunrong Li, Chimera R. Peet & Deric L. Wheeler. (2011) Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Cancer Biology & Therapy 12:5, pages 436-446.
Read now
Read now
Articles from other publishers (41)
Rohit Pal, Ghanshyam Teli, Gurubasavaraja Swamy Purawarga Matada & Prasad Sanjay Dhiwar. (2023) Designing strategies, structural activity relationship and biological activity of recently developed nitrogen containing heterocyclic compounds as epidermal growth factor receptor tyrosinase inhibitors. Journal of Molecular Structure 1291, pages 136021.
Crossref
Crossref
Wagner Gomes-Silva, Aljomar José Vechiato-Filho, Ana Cláudia Luiz, André Guollo, Maria Cecília Querido de Oliveira, Mauricio Neves Gomes, Fernanda Cunha Caparelli & Thais Bianca Brandão. (2023) Clinical characterization of stomatitis cases with an epithelial growth factor receptor inhibitor in metastatic colorectal cancer patients: A study of 7 cases and literature review. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 136:2, pages 162-172.
Crossref
Crossref
Andrés F. Cruz-Pacheco, Yeison Monsalve, Yunier Serrano-Rivero, Julieta Salazar-Uribe, Ernesto Moreno & Jahir Orozco. (2023) Engineered synthetic nanobody-based biosensors for electrochemical detection of epidermal growth factor receptor. Chemical Engineering Journal 465, pages 142941.
Crossref
Crossref
Wancai Que, Maohua Chen, Ling Yang, Bingqing Zhang, Zhichang Zhao, Maobai Liu, Yu Cheng & Hongqiang Qiu. (2021) A network pharmacology-based investigation on the bioactive ingredients and molecular mechanisms of Gelsemium elegans Benth against colorectal cancer. BMC Complementary Medicine and Therapies 21:1.
Crossref
Crossref
Pau Riera, Benjamín Rodríguez-Santiago, Adriana Lasa, Lidia Gonzalez-Quereda, Berta Martín, Juliana Salazar, Ana Sebio, Anna C. Virgili, Jordi Minguillón, Cristina Camps, Jordi Surrallés & David Páez. (2020) Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients. Cancers 12:8, pages 2245.
Crossref
Crossref
Vittoria Graziani, Assunta Esposito, Monica Scognamiglio, Angela Chambery, Rosita Russo, Fortunato Ciardiello, Teresa Troiani, Nicoletta Potenza, Antonio Fiorentino & Brigida D’Abrosca. (2019) Spectroscopic Characterization and Cytotoxicity Assessment towards Human Colon Cancer Cell Lines of Acylated Cycloartane Glycosides from Astragalus boeticus L.. Molecules 24:9, pages 1725.
Crossref
Crossref
A. Saint-Jean, N. Reguart, A. Eixarch, A. Adán, C. Castellà, B. Sánchez-Dalmau & M. Sainz–de–la–Maza. (2018) Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial. Journal Français d'Ophtalmologie 41:10, pages 955-962.
Crossref
Crossref
Giulia Cazzanelli, Flávia Pereira, Sara Alves, Rita Francisco, Luísa Azevedo, Patrícia Dias Carvalho, Ana Almeida, Manuela Côrte-Real, Maria Oliveira, Cândida Lucas, Maria Sousa & Ana Preto. (2018) The Yeast Saccharomyces cerevisiae as a Model for Understanding RAS Proteins and their Role in Human Tumorigenesis. Cells 7:2, pages 14.
Crossref
Crossref
Saimila Momin & Ganji Purnachandra Nagaraju. 2018. Role of Tyrosine Kinases in Gastrointestinal Malignancies. Role of Tyrosine Kinases in Gastrointestinal Malignancies
171
178
.
Anna E. Kersh, Spencer Ng, Yun Min Chang, Maiko Sasaki, Susan N. Thomas, Haydn T. Kissick, Gregory B. Lesinski, Ragini R. Kudchadkar, Edmund K. Waller & Brian P. Pollack. (2017) Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. The Journal of Clinical Pharmacology 58:1, pages 7-24.
Crossref
Crossref
Bin-Bin Shih, Yi-Fang Chang, Chun-Chia Cheng, Hao-Jhih Yang, Kang-Wei Chang, Ai-Sheng Ho, Hua-Ching Lin, Chun Yeh & Chun-Chao Chang. (2017) SPECT imaging evaluation of 111indium-chelated cetuximab for diagnosing EGFR-positive tumor in an HCT-15-induced colorectal xenograft. Journal of the Chinese Medical Association 80:12, pages 766-773.
Crossref
Crossref
Yung-mae M. Yao, Gregory P. Donoho, Philip W. Iversen, Youyan Zhang, Robert D. Van Horn, Amelie Forest, Ruslan D. Novosiadly, Yue Wang Webster, Philip Ebert, Steven Bray, Jason C. Ting, Amit Aggarwal, James R. Henry, Ramon V. Tiu, Gregory D. Plowman & Sheng-Bin Peng. (2017)
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with
BRAF
or
KRAS
Mutations
. Clinical Cancer Research 23:18, pages 5547-5560.
Crossref
Crossref
Emilie M. J. van Brummelen, Anthonius de Boer, Jos H. Beijnen & Jan H. M. Schellens. (2017)
BRAF
Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies
. The Oncologist 22:7, pages 864-872.
Crossref
Crossref
Ben Creavin & Desmond Winter. 2017. Coloproctology. Coloproctology
209
239
.
Xiaodong Liu, Shuo Tian, Mei Liu, Lingyan Jian & Limei Zhao. (2016) Wogonin inhibits the proliferation and invasion, and induces the apoptosis of HepG2 and Bel7402 HCC cells through NF-κB/Bcl-2, EGFR and EGFR downstream ERK/AKT signaling. International Journal of Molecular Medicine 38:4, pages 1250-1256.
Crossref
Crossref
Sripathi M. Sureban, Dongfeng Qu & Courtney W. Houchen. (2015) Regulation of miRNAs by Agents Targeting the Tumor Stem Cell Markers DCLK1, MSI1, LGR5, and BMI1. Current Pharmacology Reports 1:4, pages 217-222.
Crossref
Crossref
D Fuchs, M Metzig, M Bickeböller, C Brandel & W Roth. (2014) The Gβ5 protein regulates sensitivity to TRAIL-induced cell death in colon carcinoma. Oncogene 34:21, pages 2753-2763.
Crossref
Crossref
Kyle Knickelbein & Lin Zhang. (2015) Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes & Diseases 2:1, pages 4-12.
Crossref
Crossref
Xiaodong She, Lijue Chen, Leonora Velleman, Chengpeng Li, Canzhong He, John Denman, Tao Wang, Sarah Shigdar, Wei Duan & Lingxue Kong. (2015) The control of epidermal growth factor grafted on mesoporous silica nanoparticles for targeted delivery. Journal of Materials Chemistry B 3:29, pages 6094-6104.
Crossref
Crossref
Sandra V. Verstraeten, Cesar G. Fraga & Patricia I. Oteiza. (2015) Interactions of flavan-3-ols and procyanidins with membranes: mechanisms and the physiological relevance. Food & Function 6:1, pages 32-40.
Crossref
Crossref
Timothy R Wilson & Mark R Lackner. (2014) Changing the paradigm: circulating tumor DNA as a ‘liquid biopsy’ for clinical biomarker assessments. Clinical Investigation 4:12, pages 1083-1093.
Crossref
Crossref
Loredana Vecchione. (2014) Optimization of Anti-EGFR Treatment of Advanced Colorectal Cancer. Current Colorectal Cancer Reports 10:3, pages 263-271.
Crossref
Crossref
JUAN XIE, MING CHEN, JING ZHOU, MING-SHU MO, LI-HUI ZHU, YAN-PING LIU, QING-JUN GUI, LI ZHANG & GUO-QING LI. (2014) miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. Oncology Reports 31:4, pages 1715-1722.
Crossref
Crossref
Clinton F. Stewart, Michael Tagen, Lee S. Schwartzberg, L. Johnetta Blakely, Kurt W. Tauer & Linda M. Smiley. (2014) Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors. Cancer Chemotherapy and Pharmacology 73:3, pages 561-568.
Crossref
Crossref
Yinsheng Wang, Lidan Zha, Dan Liao & Xiaozhi Li. (2014) A Meta-Analysis on the Relations between EGFR R521K Polymorphism and Risk of Cancer. International Journal of Genomics 2014, pages 1-7.
Crossref
Crossref
Nicholas C. Dracopoli & Katie Streicher. 2014. Genomic Biomarkers for Pharmaceutical Development. Genomic Biomarkers for Pharmaceutical Development
23
49
.
Wenqi Wu, Zhenzhen Kong, Xiaolu Duan, Hanliang Zhu, Shujue Li, Shaohua Zeng, Yeping Liang, George Iliakis, Zhiming Gui & Dong Yang. (2013) Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells. Biochemical and Biophysical Research Communications 442:1-2, pages 127-132.
Crossref
Crossref
Selja Koskensalo, Johanna Louhimo, Jaana Hagström, Mikael Lundin, Ulf-Håkan Stenman & Caj Haglund. (2013) Concomitant Tumor Expression of EGFR and TATI/SPINK1 Associates with Better Prognosis in Colorectal Cancer. PLoS ONE 8:10, pages e76906.
Crossref
Crossref
Nicolas Molina-Prat, Alejandro Saint-Jean & Maite Sainz de la Maza. (2013) Author reply. Ophthalmology 120:5, pages 1104-1105.
Crossref
Crossref
Vanessa Szablewski, Jérôme Solassol, Flora Poizat, Marion Larrieux, Louis Crampette, Alain Mange, Caroline Bascoul-Mollevi & Valérie Costes. (2013) EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma. International Journal of Molecular Sciences 14:3, pages 5170-5181.
Crossref
Crossref
Mauricio Burotto, Marion L Hartley, John L Marshall & Michael J Pishvaian. (2012) Future of targeted agents in metastatic colorectal cancer. Colorectal Cancer 1:5, pages 433-443.
Crossref
Crossref
Alejandro Saint-Jean, Maite Sainz de la Maza, Merce Morral, Josep Torras, Ramon Quintana, Juan Jose Molina & Nicolas Molina-Prat. (2012) Ocular Adverse Events of Systemic Inhibitors of the Epidermal Growth Factor Receptor: Report of 5 Cases. Ophthalmology 119:9, pages 1798-1802.
Crossref
Crossref
Monica Baiula, Gioia Carbonari, Samantha D. Dattoli, Maria Calienni, Andrea Bedini & Santi Spampinato. (2012) REST is up-regulated by epidermal growth factor in HeLa cells and inhibits apoptosis by influencing histone H3 acetylation. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1823:8, pages 1252-1263.
Crossref
Crossref
ZhenZhen Hu, Jun Du, Ling Yang, YiChao Zhu, Yu Yang, DaTong Zheng, Akimasa Someya, Luo Gu & Xiang Lu. (2012) GEP100/Arf6 Is Required for Epidermal Growth Factor-Induced ERK/Rac1 Signaling and Cell Migration in Human Hepatoma HepG2 Cells. PLoS ONE 7:6, pages e38777.
Crossref
Crossref
Jung-Jin Park, Jae Youn Yi, Yeung Bae Jin, Yoon-Jin Lee, Jae-Seon Lee, Yun-Sil Lee, Young-Gyu Ko & Minyoung Lee. (2012) Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells. Biochemical Pharmacology 83:7, pages 849-857.
Crossref
Crossref
Nicholas B. La Thangue & David J. Kerr. (2011) Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nature Reviews Clinical Oncology 8:10, pages 587-596.
Crossref
Crossref
Lifeng Feng, Jin‐Tao Wang, Hongchuan Jin, Kaixian Qian & Jian‐Guo Geng. (2011) SH3KBP1‐binding protein 1 prevents epidermal growth factor receptor degradation by the interruption of c‐Cbl‐CIN85 complex. Cell Biochemistry and Function 29:7, pages 589-596.
Crossref
Crossref
Sanjay Harrison & Harrison Benziger. (2011) The molecular biology of colorectal carcinoma and its implications: A review. The Surgeon 9:4, pages 200-210.
Crossref
Crossref
Burkhard Jandrig. 2011. Cancer Risk Evaluation. Cancer Risk Evaluation
9
24
.
Pierpaolo CorrealeMaria Grazia Cusi & Pierosandro Tagliaferri. (2011) Immunomodulatory properties of anticancer monoclonal antibodies: is the ‘magic bullet’ still a reliable paradigm?. Immunotherapy 3:1, pages 1-4.
Crossref
Crossref
Kermit L. CarrawayIIIIII. (2010) E3 ubiquitin ligases in ErbB receptor quantity control. Seminars in Cell & Developmental Biology 21:9, pages 936-943.
Crossref
Crossref